相关实验视频
Updated: Jan 11, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
890
睡眠时间与超重/肥胖之间的关系:对元分析的全面概述
Mateus Assis Benfica1, Tamiles Costa Ribeiro1, Kallyane Santos Oliveira Silva1
1Programa de Pós-Graduação em Ciências da Saúde (PPGCS), Universidade Estadual de Santa Cruz (UESC), Ilhéus, Bahia, Brazil.
Clinical obesity
|November 14, 2025
概括
短时间或长时间的睡眠时间会增加所有年龄组超重和肥胖的风险. 这篇综合性综述综合了证据,强调睡眠时间是体重管理中的一个重要,可修改的因素.
科学领域:
- 公共卫生 公共卫生
- 流行病学 流行病学
- 睡眠医学 睡眠医学
背景情况:
- 全球超重和肥胖率的上升需要了解导致因素.
- 正常睡眠时间 (SD) 的变化越来越被认为是一个重要的因素.
- 存在许多带有元分析的系统性审查 (SRMA),需要对更高层次的证据进行综合.
研究的目的:
- 提供有关睡眠时间与超重/肥胖之间的关系的现有SRMA的全面概述.
- 为研究人员和临床医生综合最高水平的证据.
- 评估短时间和长时间睡眠对不同年龄组体重状况的影响.
主要方法:
- 在主要的科学数据库 (PubMed,科学网,Embase,Scopus) 中进行的搜索.
- 使用系统性审查中偏差风险 (ROBIS) 工具评估所包含的评论的质量.
- 逆方差异性模型 (IVhet) 用于组合相对风险 (RR) 和95%置信区间 (CI).
主要成果:
- 在合成中包括了18种SRMA.
- 短睡眠时间增加了年幼儿童 (RR=1.39),年长儿童 (RR=2.21),青少年 (RR=1.36) 和成年人 (RR=1.30) 的超重/肥胖风险.
- 长时间睡眠增加了成年人的风险 (RR=1.05),但在儿童中显示出保护作用 (RR=0.86).
结论:
- 睡眠时间是超重和肥胖的重要和可修改的风险因素.
- 睡眠不足和睡眠过度都与风险增加有关,年龄组之间存在差异.
- 调查结果强调了解决睡眠模式在体重管理公共卫生战略中的重要性.
相关概念视频
Insufficient Sleep and Sleep Deprivation
816
Insufficient sleep refers to not getting the recommended amount of sleep for optimal functioning, even if it's just slightly less than needed. Sleep insufficiency may occur due to lifestyle choices, such as staying up late for social events or work, resulting in routinely getting less sleep than required. For example, consistently sleeping 6 hours when the body needs 7-9 hours can lead to cumulative effects on health and well-being.
Sleep deprivation is a more severe form of sleep loss...
Sleep deprivation is a more severe form of sleep loss...
816
Sleep Apnea
464
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
464
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
230
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
230
Drug Dosing: Obese Patients
208
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
208
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
163
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
163

